Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation - SAHPRA

Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

2022 Aug

Download latest version
Document Number: DHCPL
Version: 1
Date Updated: 17/08/2022
File Type: pdf
Category: Communication To Health Care Professionals
Unit: Pharmacovigilance